La eficacia de la clonidina en la reducción de síntomas de delirio

Autores/as

  • Ahmadali Noorbala Psychosomatic Medicine Research Center, Tehran University of Medical Science, Tehran, Iran https://orcid.org/0000-0002-7798-1682
  • Mohammad Arbabi Psychosomatic Medicine Research Center, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0001-5368-2832
  • Houman Kamranian Department of Psychiatry, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran https://orcid.org/0000-0002-9780-4878
  • Zeinab Jalambadani Non-Communicable Diseases Research Center, Department of Community Medicine, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran. https://orcid.org/0000-0003-0803-7679
  • Asghar Kazemzadeh Department of Internal Medicine, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran https://orcid.org/0000-0002-1232-0429
  • Mohammadreza Shegarf Nakhaie Non-Communicable Diseases Research Center, Department of Community Medicine, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran. https://orcid.org/0000-0001-8651-1386

Palabras clave:

Clonidine, Delirium, ICU, Intensive Care

Resumen

Introducción: el uso de clonidina para aliviar los síntomas del delirio aún no ha recibido suficiente atención e investigación científica. Es fundamental utilizar medicamentos para aliviar el delirio que no solo controlen la agitación, sino que también eviten la sedación excesiva.

Objetivo: evaluar la eficacia de la clonidina para reducir los síntomas del delirio.

Métodos: se realizó un ensayo clínico aleatorizado, doble ciego, con 20 pacientes con COVID-19 que presentaban síntomas de delirio, ingresados ​​en la UCI de Teherán, Irán en 2021. Las herramientas del estudio fueron: RASS (Escala de Agitación-Sedación de Richmond), CAM-ICU (Método de Evaluación de la Confusión para la Unidad de Cuidados Intensivos) y la Lista de Verificación de Efectos Adversos de Medicamentos. Los pacientes se dividieron aleatoriamente en dos grupos: el grupo experimental (que recibió 0,1-1 mg de clonidina oral cada 12 horas) y el grupo control (que recibió comprimidos de placebo). Se analizaron los datos antes y después de la intervención.

Resultados: en el grupo placebo, 14 pacientes (93 %) experimentaron delirio, mientras que solo un paciente (5 %) del grupo clonidina desarrolló esta afección. Esta diferencia fue estadísticamente significativa (p < 0,001) con una razón de probabilidades de 0,055 (IC del 95 %: 0,010 a 0,299), lo que indica que la clonidina redujo notablemente el riesgo de delirio en pacientes con COVID-19.

Conclusiones: los resultados sugieren que la clonidina tiene una buena eficacia en la prevención del delirio en pacientes con COVID-19 ingresados ​​en una unidad de cuidados intensivos.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Ahmadali Noorbala, Psychosomatic Medicine Research Center, Tehran University of Medical Science, Tehran, Iran

Google Scholar: https://scholar.google.com/citations?hl=en&user=YcvZZ0cAAAAJ

ResearchGate: https://www.researchgate.net/profile/Ahmad-Ali-Noorbala-2

Mohammad Arbabi, Psychosomatic Medicine Research Center, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Website: https://rpis.research.ac.ir/Researcher.php?id=3635911

Google Scholar: https://scholar.google.com/citations?hl=en&user=N-RcdD0AAAAJ&view_op=list_works

Research Gate: https://www.researchgate.net/profile/Mohammad-Arbabi-3/research

Houman Kamranian, Department of Psychiatry, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

Assistant Professor

Zeinab Jalambadani, Non-Communicable Diseases Research Center, Department of Community Medicine, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Phd

Assistant Professor

Asghar Kazemzadeh, Department of Internal Medicine, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

Assistant Professor

Mohammadreza Shegarf Nakhaie, Non-Communicable Diseases Research Center, Department of Community Medicine, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Assistant Professor of Psychiatry, Fellowship in Psychosomatics, Sabzevar University of Medical Sciences, Sabzevar, Iran

Citas

1. Ng K, Shubash C, Chong J. The effect of dexmedetomidine on delirium and agitation in patients in intensive care: systematic review and meta‐analysis with trial sequential analysis. Anaesthesia. 2019;74(3):380-92.

2. Khalighi E, Tarjoman A, Abdi A, Borji M. The prevalence of delirium in patients in Iran: a systematic review and meta-analysis. Future Neurology. 2019;14(4):FNL34.

3. Coolens O, Kaltwasser A, Melms T, Monke S, Nydahl P, Pelz S, et al. Delirium management in 2024: A status check and evolution in clinical practice since 2016. Intensive and Critical Care Nursing. 2025;89:103995.

4. Blair GJ, Mehmood T, Rudnick M, Kuschner WG, Barr J. Nonpharmacologic and medication minimization strategies for the prevention and treatment of ICU delirium: A narrative review. Journal of intensive care medicine. 2019;34(3):183-90.

5. LaHue SC, James TC, Newman JC, Esmaili AM, Ormseth CH, Ely EW. Collaborative delirium prevention in the age of COVID‐19. Journal of the American Geriatrics Society. 2020;68(5):947.

6. Steardo L, Steardo Jr L, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID‐19. Acta Physiologica (Oxford, England). 2020;229(3):e13473.

7. Steardo L, Zorec R, Verkhratsky A. Neuroinfection may potentially contribute to pathophysiology and clinical manifestations of COVID‐19. Acta Physiologica. 2020 Jul;229(3):e13473. doi: 10.1111/apha.13473.

8. Lu Z, Wang X, Wang J, Zhao L, Wu Y, Sun M, et al. The intersection of delirium and long-term cognition in older adults: the critical role of delirium prevention. Journal of Neurology. 2025;272(6):1-19.

9. Ehler J, Petzold A. Haloperidol is not the “one drug fits all” solution in the treatment of delirium. Critical Care. 2025;29(1):163.

10. Glaess SS, Attridge RL, Christina Gutierrez G. Clonidine as a strategy for discontinuing dexmedetomidine sedation in critically ill patients: A narrative review. American Journal of Health-System Pharmacy. 2020;77(7):515-22.

11. Zolfaghari M, Arbabi M, Pedram Razi S, Biat K, Bavi A. Effectiveness of a multifactor educational intervention on delirium incidence and length of stay in patients with cardiac surgery. Journal of hayat. 2012;18(1):67-78.

12. Walsh TS, Parker RA, Aitken LM, McKenzie CA, Emerson L, Boyd J, et al. Dexmedetomidine-or clonidine-based sedation compared with propofol in critically ill patients: the A2B randomized clinical trial. JAMA. 2025. Advance online publication. https://doi.org/10.1001/jama.2025.7200

13. Baller EB, Hogan CS, Fusunyan MA, Ivkovic A, Luccarelli JW, Madva E, et al. Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19. Psychosomatics. 2020;61(6):585-96.

14. Howard P, Curtin J. Efficacy and safety of subcutaneous clonidine for refractory symptoms in palliative medicine: a retrospective study. BMJ Supportive & Palliative Care. 2022;13(e3):e820-e4.

15. Wang JG, Belley-Coté E, Burry L, Duffett M, Karachi T, Perri D, et al. Clonidine for sedation in the critically ill: a systematic review and meta-analysis. Crit Care. 2017;21(1):75.

16. Hov KR, Neerland BE, Andersen AM, Undseth Ø, Wyller VB, MacLullich AMJ, et al. The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses. BMC Pharmacol Toxicol. 2018;19(1):29.

17. Recchia A, Tonti MP, Mirabella L, Izzi A, Del Gaudio A. The Pharmacological Class Alpha 2 Agonists for Stress Control in Patients with Respiratory Failure: The Main Actor in the Different Acts. Stresses. 2022;3(1):1-10.

18. Rowland DC, Waldvogel NJ. Clonidine for Management of Agitation in Delirious Patients. Current Psychiatry Reports. 2025:1-7. doi: 10.1007/s11920-025-01617-5.

19. Tang F, Ng CM, Horn J, Bada HS, Leggas M. Pharmacokinetic modeling and model‐based hypothesis generation for dose optimization of clonidine in neonates with neonatal opioid withdrawal syndrome. Clinical Pharmacology & Therapeutics. 2025;117(5):1254-63.

20. Hanna J, Ghazi L, Yamamoto Y, Simonov M, Shah T, Wilson FP, et al. Excessive blood pressure response to clonidine in hospitalized patients with asymptomatic severe hypertension. American Journal of Hypertension. 2022;35(5):433-40.

Descargas

Publicado

2025-09-12

Cómo citar

1.
Noorbala A, Arbabi M, Kamranian H, Jalambadani Z, Kazemzadeh A, Shegarf Nakhaie M. La eficacia de la clonidina en la reducción de síntomas de delirio. Rev. Hosp. Psiq. Hab. [Internet]. 12 de septiembre de 2025 [citado 18 de noviembre de 2025];22. Disponible en: https://revhph.sld.cu/index.php/hph/article/view/821

Número

Vol. 22 (2025): Publicación continua

Sección

Artículo original

Licencia

Derechos de autor 2025 mohammadreza Shegarf Nakhaie

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.